Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceBusiness Wire • 05/28/26
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation UseZacks Investment Research • 05/28/26
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)Business Wire • 05/27/26
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/07/26
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial GuidanceBusiness Wire • 05/07/26
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)Business Wire • 05/04/26
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026Business Wire • 04/23/26
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?Zacks Investment Research • 03/30/26
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?Zacks Investment Research • 03/06/26
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceBusiness Wire • 03/04/26
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For ApraglutideSeeking Alpha • 02/26/26
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/25/26
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 OutlookBusiness Wire • 02/25/26
What's in Store for These 5 Medical Companies This Earnings Season?Zacks Investment Research • 02/23/26